Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.39 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.37 |
| ▸ | TACR3 | P29371 | 2/20 | 0.37 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.36 |
| ▸ | XPO1 | O14980 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4334282 | 0.86 | SCN9A (0.39) | MAPK1MAPK3SCN9ALIMK1CSNK1D | |
| SCHEMBL4335964 | 0.84 | TRPV3 (0.42) | MAPK1MAPK3ROCK2MAP2K4ROCK1 | |
| SCHEMBL4334123 | 0.83 | ROCK2 (0.43) | MAPK1MAPK3ROCK2MAP2K4ROCK1 | |
| SCHEMBL4346841 | 0.82 | ROCK1 (0.41) | MAPK1MAPK3ROCK2MAP2K4ROCK1 | |
| SCHEMBL4338871 | 0.80 | MAP2K4 (0.43) | MAPK1MAPK3MAP2K4CSNK1DMAP2K7 | |
| SCHEMBL4338629 | 0.79 | MAPK1 (0.55) | MAPK1MAPK3ROCK2ROCK1TACR3 | |
| SCHEMBL2861586 | 0.79 | MAP2K4 (0.56) | MAPK1MAP2K4XPO1 | |
| SCHEMBL4341423 | 0.78 | ROCK1 (0.39) | MAPK1MAPK3ROCK2MAP2K4ROCK1 | |
| SCHEMBL2865663 | 0.78 | DYRK1A (0.48) | MAP2K4GABRA5 | |
| SCHEMBL4334999 | 0.77 | TP53 (0.41) | MAPK1MAPK3MAP2K4CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20050282880-A1 | Novel 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203691-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | MAPK1 1/4885MAPK3 2/4885ROCK2 805/4885 |
| US-20050282880-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | MAPK1 1/4885MAPK3 2/4885ROCK2 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.